Medable Updates Digital Platform With Oncology-Focused Tools Ahead of ASCO 2025
Medable has announced the release of a new version of its digital clinical trials platform tailored specifically for oncology, ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting. The update focuses on simplifying operations for sites and sponsors while expanding access and reducing burden for cancer patients through AI-driven automation, remote participation, and electronic clinical outcome assessments (eCOAs).
The release comes as oncology trials grow in volume and complexity. A recent report cited by the company notes a mean annual increase of 266.6 oncology trials globally, and since year 2000, the number of investigational cancer drugs has nearly quadrupled. This trend is accompanied by increasing protocol complexity, rising demands for multiregional trial representation (especially under new FDA guidance) and the logistical burden of incorporating biomarker data and novel modalities like cell and gene therapies.
See also: Medable Adds Generative AI to Simplify and Speed Up Clinical Trials
Medable’s updated platform integrates AI tools, self-service configuration, and ePRO (electronic patient-reported outcomes) technology to improve trial efficiency and support continuous oversight. The system reportedly reduces site workload and visit times by digitizing assessments and enabling remote data collection—an important feature given the immunocompromised status of many cancer patients. It also offers protocol-ready libraries and site-friendly workflows designed to support rapid trial builds and adaptive study designs.
The company states that its platform has been used in nearly 400 trials across 70 countries and 120 languages, reaching over one million patients. Medable will be showcasing the updated oncology platform at Booth #10105 during ASCO 2025, taking place May 30–June 3 in Chicago.
Cover image: Medable
Topics: AI & Digital
